SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-20-021865
Filing Date
2020-08-13
Accepted
2020-08-13 16:06:42
Documents
47
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0620_tffpharma.htm 10-Q 255036
2 AMENDMENT NO. 1 DATED MAY 14, 2020 TO EXECUTIVE EMPLOYMENT AGREEMENT BETWEEN GLE f10q0620ex10-1_tffpharma.htm EX-10.1 8329
3 CERTIFICATION f10q0620ex31-1_tffpharma.htm EX-31.1 12255
4 CERTIFICATION f10q0620ex31-2_tffpharma.htm EX-31.2 12385
5 CERTIFICATION f10q0620ex32-1_tffpharma.htm EX-32.1 6162
  Complete submission text file 0001213900-20-021865.txt   1747782

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE tffp-20200630.xml EX-101.INS 236822
7 XBRL SCHEMA FILE tffp-20200630.xsd EX-101.SCH 30353
8 XBRL CALCULATION FILE tffp-20200630_cal.xml EX-101.CAL 26676
9 XBRL DEFINITION FILE tffp-20200630_def.xml EX-101.DEF 76139
10 XBRL LABEL FILE tffp-20200630_lab.xml EX-101.LAB 181740
11 XBRL PRESENTATION FILE tffp-20200630_pre.xml EX-101.PRE 137825
Mailing Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746
Business Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746 737-802-1973
TFF Pharmaceuticals, Inc. (Filer) CIK: 0001733413 (see all company filings)

IRS No.: 824344737 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39102 | Film No.: 201099334
SIC: 2834 Pharmaceutical Preparations